A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma
Latest Information Update: 25 Jan 2023
At a glance
- Drugs Pazopanib (Primary) ; Doxorubicin
- Indications Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Acronyms EPAZ
- 27 Dec 2022 Results of post hoc analysis assessing The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome published in the European Journal of Cancer
- 21 Sep 2021 Results of post-hoc analysis assessing the prognostic impact of frailty, presented at the 46th European Society for Medical Oncology Congress.
- 24 Aug 2020 Results of a German Intergroup study published in the Journal of Clinical Oncology